AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
21 hours ago
AbbVie agreed to pay up to $2.54 billion to Disco Pharmaceuticals for rights to develop AND-gated bispecific therapeutics for solid tumors. The deal marks an expansion into next-generation cancer medicines amid growing industry interest in bispecific antibodies.